Pricey Alzheimer’s Drug Coverage Hinges on FDA Decision

Bloomberg News, June 15, 2023: If Leqembi is approved, it will take time for doctors to arrange for patients to be tested for mild cognitive impairment and amyloid plaques on the brain, get the Leqembi infusions, and sign up patients for a registry. NCHR praises the CMS Registry as a good choice, but industry-funded groups complain.

Read More »

US FDA adcom supports Leqembi for full approval

BioWorld, June 9, 2023: BioWorld news explains that FDA Advisory Committee supports Leqembi for Mild Cognitive Impairment (MCI) caused by Alzheimer’s and quotes our statement that MCI can go away without drugs, which means that Leqembi’s risks of brain swelling and bleeding will often greatly outweigh the potential benefits.

Read More »

NCHR Comment on USPSTF Draft Research Plan on Interventions to Prevent Perinatal Depression

We appreciate efforts by the US Preventive Services Task Force to reduce perinatal depression, which is one of the most common complications of pregnancy. Perinatal depression contributes significantly to maternal mortality and adverse neonatal, infant, and child outcomes. We agree that developing effective interventions to prevent perinatal depression is essential to reduce the U.S. maternal mortality rate.

Read More »